The Medical Letter - 2007
Search or Select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Year:    Publication:      2007 Annual Index: U.S. English | Canadian English
January 1, 2007 (Issue 1251)  
  • Sitagliptin (Januvia) for Type 2 Diabetes   
    Sitagliptin phosphate (Januvia - Merck) is the first dipeptidyl-peptidase-4 (DPP-4) inhibitor to be marketed for treatment of type 2 diabetes. It has been approved by the FDA for oral use as...
  • Oral Oxymorphone (Opana)   
    Oxymorphone hydrochloride, a semi-synthetic opioid agonist, has been available for many years in the US as Numorphan (Endo) for parenteral use and as a rectal suppository. Now it has been...
January 15, 2007 (Issue 1252)  
  • A Low-Dose Doxycycline (Oracea) for Rosacea   
    A new once-daily, low-dose oral formulation of doxycycline monohydrate (Oracea - CollaGenex) has been approved by the FDA for treatment of inflammatory papules and pustules associated with...
  • Dasatinib (Sprycel) for CML and Ph+ ALL   
    Dasatinib (Sprycel - Bristol-Myers Squibb), an inhibitor of multiple tyrosine kinases, has been approved by the FDA for second-line treatment of chronic myelogenous leukemia (CML) and...
  • Tdap, DTaP Mix-Ups   
    Medical Letter consultants have brought to our attention some confusion that has accompanied the release of Adacel, a combination of tetanus toxoid, diphtheria toxoid and acellular...
January 29, 2007 (Issue 1253)  
February 12, 2007 (Issue 1254)  
  • Continuous Glucose Monitoring   
    A variety of glucose monitoring devices have been used in an effort to reduce the hypoglycemia and wide glucose excursions that complicate insulin treatment of diabetes. Since the last Medical...
  • Angeliq for Treatment of Menopausal Symptoms   
    A combination tablet containing estradiol and drospirenone (Angeliq - Berlex) recently became available for treatment of moderate to severe menopausal symptoms in women with an intact uterus....
February 26, 2007 (Issue 1255)  
March 12, 2007 (Issue 1256)  
March 26, 2007 (Issue 1257)  
April 9, 2007 (Issue 1258)  
  • Aliskiren (Tekturna) for Hypertension   
    Aliskiren (ah LIS ker in; Tekturna - Novartis), the first direct renin inhibitor, has been approved by the FDA for treatment of hypertension. It is indicated for oral use either as...
  • Subcutaneous Immune Globulin (SCIG)   
    Some patients with primary immune deficiency are injected with intravenous immune globulin (IVIG) every 3-4 weeks. Now a subcutaneous immune globulin (SCIG) has also been approved in the US for this...
April 23, 2007 (Issue 1259)  
May 7, 2007 (Issue 1260)  
  • Erythropoietin Safety Concerns   
    The erythropoiesis-stimulating agents (ESAs) epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp) are widely used for treatment of anemia and to reduce the need for red blood...
  • Dermal Fillers   
    Several injectable products are available for soft tissue augmentation of wrinkles and folds. These fillers are often used in conjunction with botulinum toxin type A (Botox) injections.
  • In Brief: Tegaserod (Zelnorm) Withdrawn   
    Tegaserod maleate (Zelnorm – Novartis), a partial serotonin 5-HT4 receptor agonist that increases gastrointestinal motility, was approved by the FDA in 2002 for short-term treatment of...
May 20, 2007 (Issue 1261)  
  • A New Sunscreen Agent   
    Ecamsule (terephthalylidene dicamphor sulfonic acid), the first new sunscreen agent to be approved by the FDA in 18 years, is now available in the US in a moisturizer called Anthelios SX....
  • Insulin-like Growth Factor-1 for Severe Growth Failure   
    Mecasermin (Increlex - Tercica), which is injected subcutaneously, has been approved by the FDA for treatment of growth failure in children with severe primary insulin-like growth factor...
June 4, 2007 (Issue 1262)  
June 18, 2007 (Issue 1263)  
  • Treatment of Lyme Disease   
    Superseded by The Medical Letter "Treatment of Lyme Disease" - Issue 1494, May 9, 2016Most cases of Lyme disease in North America occur between May and September. In 2005, 12 states (CT, DE,...
  • ThermaClear for Acne   
    The FDA has approved ThermaClear (Therative), a battery-powered, handheld device, to treat individual acne lesions with heat. ThermaClear is indicated only for use on mild to moderate...
  • In Brief: Orlistat OTC for Weight Loss   
    The FDA has approved over-the-counter (OTC) sale of the weight-loss drug orlistat (Xenical – Roche)1 as alli (GlaxoSmithKline), to be used in combination with a reduced-calorie,...
July 2, 2007 (Issue 1264)  
  • Arformoterol (Brovana) for COPD   
    Arformoterol tartrate (Brovana - Sepracor), a singleisomer, long-acting beta2-agonist, has been approved by the FDA as an inhalation solution for nebulization for treatment of...
  • Resperate for Hypertension   
    The FDA has approved the marketing of Resperate (InterCure), a device that helps patients breathe slowly, as an adjunct for treatment of hypertension. The FDA does not require proof of...
  • In Brief: Testing for Ovarian Cancer   
    Recent publicity about symptoms of ovarian cancer will prompt many questions from patients about testing for the disease. Early-stage epithelial ovarian cancer is potentially curable, with survival...
July 16, 2007 (Issue 1265)  
July 30, 2007 (Issue 1266)  
  • Lybrel - A Continuous Oral Contraceptive   
    Lybrel (Wyeth) is the first FDA-approved low-dose combination oral contraceptive taken 365 days a year without a placebo or pill-free interval. All tablets contain low doses of levonorgestrel...
  • Drugs for Community-Acquired Bacterial Pneumonia   
    Most patients with community-acquired pneumonia (CAP) are treated empirically. New guidelines published jointly by the Infectious Diseases Society of America and the American Thoracic Society have...
  • Corrections: Lyme Disease   
    Superseded by The Medical Letter "Treatment of Lyme Disease" - Issue 1494, May 9, 2016(Med Lett Drugs Ther 2007; 49:49) The PR interval in the table on page 50 and at the top of the first...
August 13, 2007 (Issue 1267)  
  • Reducing Intake of Trans Fatty Acids   
    The New York City Board of Health has recently required that city restaurants reduce the content of industrially produced trans fatty acids so that each serving contains
  • Probiotics   
    Superseded by The Medical Letter "Probiotics Revisited" - Issue 1407, January 7, 2013Probiotics are live, nonpathogenic microorganisms (usually bacteria or yeasts) that have been used for...
August 27, 2007 (Issue 1268)  
September 10, 2007 (Issue 1269)  
September 24, 2007 (Issue 1270)  
October 8, 2007 (Issue 1271)  
  • Influenza Vaccine 2007-2008   
    Superseded by The Medical Letter "Influenza Vaccine for 2018-2019" - Issue 1558, October 22, 2018Annual immunization against influenza A and B is the most effective method of preventing...
  • Blood Test for Tuberculosis   
    Quantiferon - TB Gold (Cellestis) is a T-cell interferon-gamma release assay approved by the FDA as an alternative to the tuberculin skin test for diagnosis of infection with Mycobacterium...
  • Addendum: Sunscreens and DEET   
    Superseded by The Medical Letter "Sunscreens" - Issue 1553, August 13, 2018An article (Med Lett Drugs Ther 2007; 49:41) on sunscreens in the May 21 issue of The Medical Letter included...
  • Correction: Low Dose Transdermal Estrogens   
    The Medical Letter article (Med Lett Drugs Ther 2007; 49:71) on Low-Dose Transdermal Estrogens said that Elestrin has been marketed in Europe since 1976. Actually it is EstroGel...
October 22, 2007 (Issue 1272)  
November 5, 2007 (Issue 1273)  
November 19, 2007 (Issue 1274)  
  • BRCA Screening   
    Direct-to-consumer advertisements are urging women to be tested for mutations in BRCA1 and BRCA2 genes, which are the most common known causes of an inherited predisposition to breast...
  • Formoterol (Perforomist) for COPD   
    Formoterol fumarate (Perforomist - Dey), a long-acting beta2-agonist, was recently approved by the FDA as an inhalation solution for nebulization for maintenance treatment of...
  • SSRIs and Osteoporosis   
    Some recently published studies suggest that taking selective serotonin reuptake inhibitors (SSRIs) may increase the risk of developing osteoporosis. A relationship between SSRIs and osteoporosis is...
  • In Brief: Varenicline (Chantix) Revisited   
    When the nicotine receptor partial agonist varenicline (Chantix – Pfizer) was first marketed, The Medical Letter concluded that it was moderately effective in increasing smoking...
December 3, 2007 (Issue 1275)  
December 17, 2007 (Issue 1276)